ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "autoimmune diseases"

  • Abstract Number: PP21 • ACR Convergence 2022

    What Lies Beneath: Making Rheumatoid Arthritis Visible for the Seronegative Patient Through Blood Work

    Shilpa Venkatachalam, Global Healthy Living Foundation, New York, NY

    Background/Purpose: When I first received my Rheumatoid Arthritis (RA) diagnosis 5 years ago, I experienced a combination of relief and disbelief. Relief because now all…
  • Abstract Number: 0006 • ACR Convergence 2022

    Oral Administration of a Novel Pyrrolopyrimidine Derivative That Inhibits BAFF Signaling Suppresses B Cell Differentiation and Production of Autoantibody in Autoimmune Model Mice

    Keiko Yoshimoto1, Katsuya Suzuki2, Yumi Ikeda1, Tsutomu Takeuchi3 and Yuko Kaneko4, 1Div. of Rheumatology, Keio University School of Medicine, Tokyo, Japan, 2Div. of Rheumatology, Keio University School of Medicine, Shinjuku, Japan, 3Keio University and Saitama Medical University, Tokyo, Japan, 4Keio University, Tokyo, Japan

    Background/Purpose: We reported that the expression level of a BAFF receptor (BR3) was upregulated in peripheral monocytes of patients with primary Sjogren's syndrome (pSS) and…
  • Abstract Number: 0136 • ACR Convergence 2022

    Sarcoidosis Incidence After mTOR Inhibitor Treatment

    Matthew Baker1, Emese Vágó2, Yuhan Liu1, Rong Lu1, Suzanne Tamang3, Erzsébet Horváth-Puhó2 and Henrik Sørensen2, 1Stanford University, Stanford, CA, 2Aarhus University Hospital, Aarhus, Denmark, 3Stanford Center for Population Health Sciences, Redwood City, CA

    Background/Purpose: Mechanistic target of rapamycin (mTOR) inhibitors are effective in animal models of granulomatous disease, but their benefit in patients with sarcoidosis is unknown. We…
  • Abstract Number: 0351 • ACR Convergence 2022

    The Effect of Belimumab to Achieve Low Disease Activity or Remission Based on SLE-DAS in Systemic Lupus Erythematosus: A Single-center Retrospective Study

    Yasuhiro Hasegawa1, Yoshiyuki Arinuma2, Yu Matsueda1, Kenji Oku3 and Kunihiro Yamaoka4, 1Kitasato University School of Medicine, Sagamihara, Japan, 2Kitasato University, Kanagawa, Japan, 3Kitasato University, Chigasaki, Japan, 4Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan

    Background/Purpose: Low disease activity (LDA) and remission in patients with systemic lupus erythematosus (SLE) can reduce organ damage accrual and improve prognosis. We investigated the…
  • Abstract Number: 0622 • ACR Convergence 2022

    Commensal Reactive T-cells Display Diverse Phenotype in Rheumatoid Arthritis Patients

    Sumbul Afroz1, Lea Williams1, Ruozhang Xu1, Joshua F. Baker2, Anupama Shahane2 and Laura F. Su3, 1Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 2Perelman School of Medicine, Philadelphia, PA, 3Department of Medicine, Division of Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Past studies have shown a critical link between alteration in human commensal microbiota and development of Rheumatoid Arthritis (RA), however how CD4+ T-cell responses…
  • Abstract Number: 0716 • ACR Convergence 2022

    Posttraumatic Stress Disorder Symptoms in Systemic Autoimmune Rheumatic Disease Patients During the Early COVID-19 Pandemic

    Jack Ellrodt1, Emily G Oakes1, Laura Kubzansky2, Karestan Koenen2, Hongshu Guan1 and Karen Costenbader1, 1Brigham and Women's Hospital, Boston, MA, 2Harvard TH Chan School of Public Health, Boston, MA

    Background/Purpose: Posttraumatic Stress Disorder (PTSD), a complex psychiatric disorder that can result from experiencing or witnessing a traumatic event, such as an accident, assault, or…
  • Abstract Number: 0770 • ACR Convergence 2022

    Immune Related Adverse Events in Checkpoint Inhibitor Treated Cancer Patients Increased in Patients with Underlying Autoimmune Disease and Positive Autoantibodies

    Amarah Baluch1, Katerina Warda2, Taylor Middleton2, Kiersten Kennedy2, Andras Perl3 and Jihad Ben Gabr1, 1SUNY Upstate Medical University, Syracuse, NY, 2SUNY Upstate Medical Unviersity, Syracuse, NY, 3SUNY, Syracuse, NY

    Background/Purpose: Immune check point inhibitors (ICIs) boost the patient's immune system by blocking intrinsic down-regulators of immunity by signaling through cytotoxic T-lymphocyte antigen 4 (CTLA-4),…
  • Abstract Number: 0874 • ACR Convergence 2022

    A Tale of Many Canadas: Associations of Ethnicity with Juvenile Idiopathic Arthritis Categories and Disease Severity at Presentation in a Multicultural Universal Healthcare Setting: Results from ReACCh-Out

    Stephanie Wong1, Lori Tucker2, Kristin Houghton3, David Cabral4, Mercedes Chan2, Ross Petty3, Andrea Human2, Kimberly Morishita3, Rae Yeung5, Kiem Oen6, Ciaran Duffy7, Roberta Berard8, Gaelle Chedeville9, Thomas Loughin10, Matthew Berkowitz10 and Jaime Guzman11, 1University of British Columbia, Vancouver, BC, Canada, 2British Columbia Children's Hospital, Vancouver, BC, Canada, 3University of British Columbia - Vancouver, Vancouver, BC, Canada, 4BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, 5The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, 6University of Manitoba, Toronto, ON, Canada, 7University of Ottawa, Ottawa, ON, Canada, 8London Health Sciences Centre, London, ON, Canada, 9McGill University, Montréal, QC, Canada, 10Simon Fraser University, Vancouver, BC, Canada, 11University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada

    Background/Purpose: The distribution of Juvenile Idiopathic Arthritis (JIA) categories and disease severity at presentation vary across countries, however it is unclear how much of this…
  • Abstract Number: 1138 • ACR Convergence 2022

    Whole-Blood DNA Methylation Analysis Reveals Respiratory Environmental Traits Involved in COVID-19 Severity Following SARS-CoV-2 Infection and Common Molecular Signatures with Autoimmune Diseases

    Guillermo Barturen1, Elena Carnero-Montoro1, Manuel Martinez-Bueno1, Silvia Rojo-Rello2, Beatriz Sobrino3, Clara Alcántara-Domínguez4, David Bernardo5 and Marta Alarcon-Riquelme1, 1Center for Genomics and Oncological Research (GENYO), Granada, Spain, 2Hospital Clínico Universitario, Valladolid, Spain, 3Hospital Regional de Málaga, Málaga, Spain, 4Lorgen G.P., SL, Granada, Spain, 5Universidad de Valladolid-CSIC, Valladolid, Spain

    Background/Purpose: SARS-CoV-2 causes a severe inflammatory syndrome (COVID-19) leading, in many cases, to bilateral pneumonia, severe dyspnea and in ~5% of these, death. DNA methylation…
  • Abstract Number: 1341 • ACR Convergence 2022

    Clinical Outcomes of COVID-19 Vaccination and Booster in Patients with Autoimmune Inflammatory Rheumatic Diseases

    Silera Holguin Balbuena, Anna Radisic, Sarah Goodman, Shreya Gor, Beatrice Wood, Alexander Shahin, Kelara Samuel, Rahul Mhaskar and John Carter, University of South Florida, Tampa, FL

    Background/Purpose: The spread of COVID-19 began in December 2019 and quickly escalated into a global pandemic resulting in millions of deaths. Many factors are associated…
  • Abstract Number: 1628 • ACR Convergence 2022

    The Sjogren Tool for Assessing Response (STAR): Assessment of Response Rates Overall, According to Baseline Activity and by Domain: Reanalysis of 9 Clinical Trials in Primary Sjogren Syndrome

    Raphaèle Seror1, Gabriel Baron2, Divi CORNEC3, Elodie Perrodeau2, Marine Camus4, Professor Simon Bowman5, Michele Bombardieri6, Hendrika Bootsma7, Suzanne Arends7, jacques-eric gottenberg8, Benjamin A. Fisher9, Wolfgang Hueber10, Joel Van Roon11, Valerie Devauchelle12, Liseth de Wolff13, Peter Gergely14, Xavier Mariette15 and Raphaël Porcher16, 1University Hospital Paris-Saclay, Le Kremlin Bicêtre, France, 2AP-HP Hôtel Dieu Hospital, Université Paris Descartes, Paris, France, 3CHRU Brest, Brest, France, 4Department of Rheumatology, Université Paris-Saclay, APHP Hôpital Bicêtre, Le Kremlin Bicêtre, France, 5University Hospitals Birmingham, Birmingham, United Kingdom, 6Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University, London, United Kingdom, 7University Medical Center Groningen, Groningen, Netherlands, 8Strasbourg University Hospital, Strasbourg, France, 9University of Birmingham, Birmingham, United Kingdom, 10Novartis Pharmaceuticals, Basel, Switzerland, 11Rheumatology & Clinical Immunology, University of Utrecht, Utrecht, Netherlands, 12Université de Bretagne Occidentale, Brest, France, 13UMCG, Zwolle, Netherlands, 14Novartis Pharma, Basel, Switzerland, 15Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, 16Université Paris Cité, Hôtel-Dieu, Paris, France

    Background/Purpose: The ESSDAI and ESSPRI, used alone, are not able to capture all features of primary Sjögren's syndrome (pSS). The NECESSITY consortium developed the Sjögren's…
  • Abstract Number: 1836 • ACR Convergence 2022

    Schizophrenia and Its Relationship with Autoimmunity: A Nationwide Analysis

    Faria Sami1, Dennis Kumi1, Sumbul Liaqat2 and Hania Sami3, 1John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, 2Rush University Medical Center, Chicago, IL, 3Shalamar Medical and Dental College, Chicago, IL

    Background/Purpose: It has been hypothesized that autoimmunity may play a role in the pathophysiology of schizophrenia (SCZ). Several autoimmune disorders (AID) have also been noted…
  • Abstract Number: 2182 • ACR Convergence 2022

    mRNA Vaccine Against Fibroblast Activation Protein Ameliorates Murine Models of Inflammatory Arthritis

    Xiaowei Zhang1, Antony Jozic1, Pingfang Song1, Qiang Xu2, Xiaofei Shi3, Hong Wang4, Lindsey Bishop1, Hillary Struthers1, John Rutledge5, Shuang Chen1, Fei Xu1, Meaghan Hancock1, Daocheng Zhu6, Gaurav Sahay1 and Cong-Qiu Chu1, 1Oregon Health & Science University, Portland, OR, 2Guangzhou University of Chinese Medicine, Guangzhou, China, 3Henan University of Science and Technology, Luoyang, China, 4Wenzhou Medical University, Wenzhou, China, 5Portland VA Research Foundation, Portland, 6Shanghai Kexin Biotechnology, Shanghai, China

    Background/Purpose: Synovial fibroblasts in patients with rheumatoid arthritis (RA) contribute substantially to the perpetuation of synovitis and invasion to cartilage and bone, and have been…
  • Abstract Number: PP23 • ACR Convergence 2022

    The Journey to Collaborative Care and Patient-Centric Educational Opportunities for a Scleroderma Patient

    Amy Gietzen and Hannah Bowen, The Ann Steffens Scleroderma Foundation, Albany, NY

    Background/Purpose: In 2001 I started to experience forearm, elbow, and wrist pain. My fingers were constantly swollen, and sensitive. After 6 months of living in…
  • Abstract Number: 0008 • ACR Convergence 2022

    CD11c+ T-Bet+ B Cells Traffic to Human Bone Marrow

    Jennifer Barnas1, Diana Alzamareh2, Nida Meednu2 and Jennifer Anolik2, 1University of Rochester, Rochester, NY, 2University of Rochester Medical Center, Rochester, NY

    Background/Purpose: CD11c+ age/autoimmunity-associated B cells (ABC) are associated with autoantibody producing cells and disease flare in systemic lupus erythematosus. ABC were initially identified in aged…
  • « Previous Page
  • 1
  • …
  • 63
  • 64
  • 65
  • 66
  • 67
  • …
  • 101
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology